3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
19
Triple Negative Breast Neoplasms
6
Prostatic Neoplasms
5
Pancreatic Neoplasms
4
Neoplasm Metastasis
3
Prostatic Neoplasms, Castration-Resistant
2
Ovarian Neoplasms
2
Melanoma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Primary Myelofibrosis
1
Primary Breast Cancer ER+ve
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Squamous Cell
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Liver Neoplasms
1
Liposarcoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Interventions
pembrolizumab
3
spartalizumab
2
sargramostim
2
trametinib
1
tislelizumab
1
nazartinib
1
fludarabine phosphate
1
enzalutamide
1
canakinumab
1
bemarituzumab
1
Specimen Handling
1
Midazolam
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Interleukin-13
1
IFL protocol
1
Fulvestrant
1
Fluorodeoxyglucose F18
1
Cyclophosphamide
1
Cetuximab
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
enzalutamide
×
Breast
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled